The treatment for glioblastoma multiforme (GBM) has not changed for more than 20 years
while the prognosis for the patients is still poor and most of them survive less than 1 year …

Introduction Glioblastoma (GBM), the most frequent type of brain tumour in adults, is highly
aggressive and invasive. No curative treatment is currently available for GBM; patient …

We have developed a systematic approach for the discovery and evaluation of local
treatment strategies for brain tumors using polymers. We demonstrated the feasibility of …

Among central nervous system tumors, Glioblastoma (GBM) is the most common, aggressive
and neurological destructive primary brain tumor in adults. Standard care therapy for GBM …

Glioblastoma multiforme (GBM) has several distinctive characteristics linked to a poor early-
stage prognosis. The crucial obstacle in the treatment of GBM is the inability of chemo drugs …

Overall survival of patients with newly diagnosed glioblastoma (GBM) remains dismal at 16
months with state-of-the-art treatment that includes surgical resection, radiation, and …

Brain cancers, mainly high-grade gliomas/glioblastoma, are characterized by uncontrolled
proliferation and recurrence with an extremely poor prognosis. Despite various conventional …

Glioblastoma multiforme (GBM) is the most common form of primary brain cancer and has
the highest morbidity rate and current treatments result in a bleak 5-year survival rate of …

Glioblastoma (GBM) is the most aggressive malignant brain tumor and is associated with a
very poor prognosis. The standard treatment for newly diagnosed patients involves total …

Polymeric drugs carrying glycolipids have been designed as target macromolecules for the
treatment of brain tumours. A methacrylate derivative of oleyl 2-acetamido-2-deoxy-α-d …